Delivery strategies of RNA therapeutics to leukocytes

Dana Tarab-Ravski; Lior Stotsky-Oterin; Dan Peer

doi:10.1016/j.jconrel.2022.01.016

Delivery strategies of RNA therapeutics to leukocytes

Dana Tarab-Ravski, Lior Stotsky-Oterin, Dan Peer

Tel Aviv University

Research output: Contribution to journal › Article › peer-review

Abstract

Harnessing RNA-based therapeutics for cancer, inflammation, and viral diseases is hindered by poor delivery of therapeutic RNA molecules. Targeting leukocytes to treat these conditions holds great promise, as they are key participants in their initiation, drug response, and treatment. The various extra- and intra-cellular obstacles that impediment the clinical implementation of therapeutic RNA can be overcome by utilizing drug delivery systems. However, delivery of therapeutic RNA to leukocytes poses an even greater challenge as these cells are difficult to reach and transfect upon systemic administration. This review briefly describes the existing successful delivery strategies that efficiently target leukocytes in vivo and discuss their potential clinical applicability.

Original language	English
Pages (from-to)	362-371
Number of pages	10
Journal	Journal of Controlled Release
Volume	342
DOIs	https://doi.org/10.1016/j.jconrel.2022.01.016
State	Published - Feb 2022

Keywords

Drug delivery
Leukocytes
Nanocarriers
RNA
mRNA

All Science Journal Classification (ASJC) codes

Pharmaceutical Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jconrel.2022.01.016

Cite this

@article{ce6a9108049b447485c7d80069326de4,

title = "Delivery strategies of RNA therapeutics to leukocytes",

abstract = "Harnessing RNA-based therapeutics for cancer, inflammation, and viral diseases is hindered by poor delivery of therapeutic RNA molecules. Targeting leukocytes to treat these conditions holds great promise, as they are key participants in their initiation, drug response, and treatment. The various extra- and intra-cellular obstacles that impediment the clinical implementation of therapeutic RNA can be overcome by utilizing drug delivery systems. However, delivery of therapeutic RNA to leukocytes poses an even greater challenge as these cells are difficult to reach and transfect upon systemic administration. This review briefly describes the existing successful delivery strategies that efficiently target leukocytes in vivo and discuss their potential clinical applicability.",

keywords = "Drug delivery, Leukocytes, Nanocarriers, RNA, mRNA",

author = "Dana Tarab-Ravski and Lior Stotsky-Oterin and Dan Peer",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier B.V.",

year = "2022",

month = feb,

doi = "10.1016/j.jconrel.2022.01.016",

language = "الإنجليزيّة",

volume = "342",

pages = "362--371",

journal = "Journal of Controlled Release",

issn = "0168-3659",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Delivery strategies of RNA therapeutics to leukocytes

AU - Tarab-Ravski, Dana

AU - Stotsky-Oterin, Lior

AU - Peer, Dan

PY - 2022/2

Y1 - 2022/2

N2 - Harnessing RNA-based therapeutics for cancer, inflammation, and viral diseases is hindered by poor delivery of therapeutic RNA molecules. Targeting leukocytes to treat these conditions holds great promise, as they are key participants in their initiation, drug response, and treatment. The various extra- and intra-cellular obstacles that impediment the clinical implementation of therapeutic RNA can be overcome by utilizing drug delivery systems. However, delivery of therapeutic RNA to leukocytes poses an even greater challenge as these cells are difficult to reach and transfect upon systemic administration. This review briefly describes the existing successful delivery strategies that efficiently target leukocytes in vivo and discuss their potential clinical applicability.

AB - Harnessing RNA-based therapeutics for cancer, inflammation, and viral diseases is hindered by poor delivery of therapeutic RNA molecules. Targeting leukocytes to treat these conditions holds great promise, as they are key participants in their initiation, drug response, and treatment. The various extra- and intra-cellular obstacles that impediment the clinical implementation of therapeutic RNA can be overcome by utilizing drug delivery systems. However, delivery of therapeutic RNA to leukocytes poses an even greater challenge as these cells are difficult to reach and transfect upon systemic administration. This review briefly describes the existing successful delivery strategies that efficiently target leukocytes in vivo and discuss their potential clinical applicability.

KW - Drug delivery

KW - Leukocytes

KW - Nanocarriers

KW - RNA

KW - mRNA

UR - http://www.scopus.com/inward/record.url?scp=85123031442&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2022.01.016

DO - 10.1016/j.jconrel.2022.01.016

M3 - مقالة

C2 - 35041904

SN - 0168-3659

VL - 342

SP - 362

EP - 371

JO - Journal of Controlled Release

JF - Journal of Controlled Release

ER -

Delivery strategies of RNA therapeutics to leukocytes

Abstract

Keywords

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this